

Protecting and Enforcing Life Science Inventions in Europe

under EPC and EU Law - From Antibodies to Zebrafish

von

Dr. rer. nat. Franz-Josef Zimmer, Steven M. Zeman, Steven Zeman, Dr. Jens Hammer, Dr.-Ing. Klara Goldbach, Dr.
Bernd Allekotte

2nd edition, completely revised and updated



Verlag C.H. Beck München 2015

Verlag C.H. Beck im Internet:

www.beck.de

ISBN 978 3 406 47351 7

Zu [Leseprobe](#) und [Inhaltsverzeichnis](#)

schnell und portofrei erhältlich bei beck-shop.de DIE FACHBUCHHANDLUNG

Index

- Amino acid sequences** 37
 - Sequence listing 37
- Animal varieties** 14
 - Claims embracing animal varieties
 - allowable 316, 317
 - No definition in EPC – plant standard likely applicable 16
 - Taxonomical rank 16
- Animals**
 - Animal varieties 15, 315
 - Application of same standards as for plant varieties 15, 301, 302, 316, 317
 - Definition of 301, 315, 316
 - Exclusion from patentability: Legal basis 4, 15, 315, 317, 328
 - Interpretation in case law 315, 317, 319
 - Discoveries 303, 328
 - Essentially biological processes 16, 305, 306, 309, 315, 318, 319, 329
 - Morality and ordre public 303, 304, 311–314
 - Parts of animals 322
 - Process claims 307, 319, 325
 - Product claims 305, 314, 317, 323
 - Product-by-process claims 20, 304, 305, 317, 323
 - Sufficiency of disclosure 302
 - Use claims 309, 321, 327
 - Use of for drug farming 305
- Antibodies** 184
 - Binding characteristics 201
 - implicit structural feature 201
 - Clarity 200
 - Discoveries 185
 - Industrial application 195
 - Inventive step 189
 - Monoclonal antibodies, when polyclonal antibodies known 223
 - Methods of treatment 186
 - Monoclonal antibodies as mere alternatives 192, 193
 - Morality and ordre public 186
 - Novelty 186
 - Process claims 216
 - From hybridoma 217
 - Synthesis by recombinant host 216
 - Product claims 203
 - Antibody as an essential element 215
 - Encoded by a nucleic acid 210
 - Functional features 205
 - Isolation from nature 216
 - Parameters 209
 - Structure 210
 - Product-by-process claims 201, 202, 205, 213, 214
 - Sufficiency of disclosure 195
 - Use claims 218
- Antitrust** 382
- Anton Piller Order** 378
- Bifurcation** 377
- Biological material**
 - Relation to need for deposit 38
- Biotech Directive** 1–3, 5, 12, 13, 267, 281, 373
- Block Exemption Regulation** 382
- Bolar Provision** 368
- Border seizure** 376
- Burden of proof**
 - Sufficiency of disclosure 102, 104, 235
- Cease and desist letter** 375
- Claim categories** 46
 - Clarity 47
 - Medicinal products 51
 - Diagnostics 51, 52
 - Surgery 51, 52
 - Treatment of the human body 51, 52
 - Process claims 46
 - Protection for directly produced product (Art. 64(2) EPC) 46
 - Product claims 46
 - Product-by-process claims 46
 - Purpose-limited product claims 46
 - Relevant date for admissibility when presented in combination with second medical use claims 72
 - Use claims 46

- Second medical use claim, relevant date for admissibility in combination with purpose-limited product claims 72
- Claim examples**
 - Animals
 - Process claims, natural animals 307
 - Process claims, parts of animals 325
 - Process claims, transgenic animals 319
 - Product claims, natural animals 305
 - Product claims, parts of animals 323
 - Product claims, transgenic animals 314, 317
 - Use claims, natural animals 309
 - Use claims, parts of animals 327
 - Use claims, transgenic animals 321
 - Antibodies
 - Process claims, by isolation from natural environment 216
 - Process claims, by secretion from hybridoma 217
 - Process claims, by synthesis from recombinant host cell 216
 - Product claims, by antibodies as essential elements 215
 - Product claims, by coding sequence of DNA 210
 - Product claims, by functional terms 205
 - Product claims, by parameters 209
 - Product claims, by process of preparation 213
 - Product claims, by structure 211
 - Use claims (including medical uses) 218
 - Human body
 - Cosmetic process claims 332
 - Process claims for preparing human beings 332
 - Process claims for preparing products involving treatment of body 332
 - Human body parts
 - Process claims 335
 - Product claims 334
 - Use claims 337
 - Human stem cells
 - Product claims 340
 - Low molecular products and polymers
 - Process claims 77
 - Product claims 73
 - Use claims (including medical uses) 78
 - Microorganisms
 - Process claims, microorganism used 248
 - Process claims, preparation of microorganisms 245
 - Product claims, by deposit number 244
 - Product claims, by functional terms 239
 - Product claims, by parameters 242
 - Product claims, by specified DNA or plasmid 240
 - Product-by-process claims 243
 - Use claims (including medical uses) 251
 - Nucleic acids
 - Process claims, isolation from nucleic acid source 134
 - Process claims, preparation of nucleic acids 132
 - Product claims, by deposit 124
 - Product claims, by encoded amino acid sequence 117
 - Product claims, by functional terms 111
 - Product claims, by nucleic acid sequence 119
 - Product claims, by nucleic acid type and methods of using same 129
 - Product claims, by nucleic acids as essential elements 127
 - Product claims, by parameters 122
 - Product claims, by process of preparation 125
 - Use claims (including medical uses) 135
 - Plants
 - Process claims, highly differentiated parts of plants 293
 - Process claims, hybrid plants 276
 - Process claims, natural plants 270
 - Process claims, transgenic plants 285
 - Process claims, undifferentiated/poorly differentiated parts of plants 298
 - Product claims, highly differentiated parts of plants 290
 - Product claims, hybrid plants 275
 - Product claims, natural plants 269
 - Product claims, transgenic plants 282
 - Product claims, undifferentiated/poorly differentiated parts of plants 296
 - Use claims, highly differentiated parts of plants 295

- Use claims, hybrid plants 278
- Use claims, natural plants 274
- Use claims, transgenic plants 288
- Use claims, undifferentiated/poorly differentiated parts of plants 299
- Proteins
 - Process claims, by isolation from natural environment 179
 - Process claims, by synthesis from recombinant host cell 180
 - Product claims, by coding sequence of DNA 171
 - Product claims, by functional terms 166
 - Product claims, by parameters 168
 - Product claims, by process of preparation 175
 - Product claims, by proteins as essential elements 177
 - Product claims, by structure 172
 - Use claims (including medical uses) 183
- Zebrafish 311, 326
- Claim interpretation** 143
 - Antibodies
 - Specifically reactive 203
 - Claim boundary relevant for clarity, not for sufficiency of disclosure 237
 - Clarity 165
 - Reference to specification 200, 201
 - Considering specification 165
 - Meaning of “isolated” 142
 - Meaning of “pharmaceutical formulation” 194
 - Meaning of “suitable for” 145
 - Mind willing to understand 237
- Clarity** 47
 - Antibodies 200
 - Arbitrary designations 108, 166
 - Claim breadth 109
 - Claim interpretation 165, 237
 - Claim not unclear just because broad 265
 - Complexity of claim 47, 48
 - Consistent terminology 265
 - Contradiction between claims and specification 165, 202
 - Determinability of claim boundary crucial 202, 236–238
 - Disclaimer 48, 49
 - During opposition 162
 - Functional features 48, 106, 107, 162, 200, 235, 236
 - Homology 109
 - Hybridizing conditions 108, 109
 - Measurement error 163
 - Medical use
 - Functional definition 164, 165
 - Need for formal definition 265
 - Nucleic acids 106
 - Parameters 48
 - Unusual parameter 48
 - Plants 264
 - Proteins 161
 - Scope of claim 47
 - The term “substantially” 264
 - View of skilled person 236
- Community Plant Variety Rights** see “CPVR”
- Contributory infringement** 367
- Costs** 344
- CPVR** 3, 6, 14, 66–69, 366
 - Duration 68
 - Formal requirements 67
 - Application 67
 - Plant varieties 66
 - Definition 66
 - Patentability (Exclusion of) 14
 - Rights conferred by 68, 69
 - Substantive requirements 67
 - Distinctiveness 67, 68
 - Novelty 67, 68
 - Stability 67, 68
 - Uniformity 67, 68
 - Form: positive and negative right 68
 - History 1
 - Only for plant varieties 66
- Criminal proceedings** 375
- Cross border Issues** 345
- Cross-label use** 361
- Decision on the merits** 377
- Decisions** Annex 10
- Deposit**
 - Accession number 38
 - Animals 304
 - Applicant and depositor identical 39, 229
 - Application to antibody inventions 196, 197
 - Application to microorganism inventions 219, 244
 - Application to nucleic acid inventions 124
 - Application to plant inventions 255
 - Budapest treaty 39

- Formal requirements 39
- Legal basis 4, 5, 38, 39
- Need for 226
 - Classical selection techniques 228, 229
 - Concept of laboriousness / undue burden inapplicable 227
 - Necessary if availability doubtful 228
 - Necessary if description alone not enabling 157
 - Necessary when microorganism not available to public 227
 - Necessary when microorganism of nonspecific origin 228
 - Unnecessary despite intermittent unavailability of strains 226, 227
 - Unnecessary if availability to public proved 227–228
 - Unnecessary if description completely enabling 102, 226, 227
- Old and new wording of Rule 31 EPC 267
- Plants 255, 266, 296
- Recognized depository institution 38, 39
- Timing of 228
- Description** 54
 - Divisional applications 54
 - Experimental data 54
 - Parameters 54
 - Measurement method 54
- Diagnostic use claims**
 - Classification as diagnostic method 24, 25
- Direct infringement** 367
- Discoveries** 80, 138
 - Animals 303, 328
 - Antibodies 185
 - Exclusion from patentability 3, 5, 7, 8
 - Microorganisms 220
 - Natural products 80, 83, 138
 - No “discovery” if product obtained by technical process 7, 8
 - Nucleic acids 80
 - Plants 266, 269, 300
 - Proteins 138
 - Relationship to industrial applicability 8
- Discovery (in litigation)** 378
- Divisional applications** 56
 - Content 58
 - Correction of 58
 - Pending application 57
 - Time limit 56, 57
 - Appeal 57
- Grant 57
- Pending application 57
- Doctrine of Equivalents** 350
- Enforcement Directive** 378
- Equivalent infringement** 350
- Essentially biological processes** 16
 - Animals 16–20, 305, 306, 309, 318, 319, 329
 - Interpretation in case law 306, 309, 318, 319
 - Microorganisms 220
 - Plants 16–20, 253, 255, 269, 273, 276, 284, 300
 - Interpretation in case law 255, 269
 - Production of plant or animal 16
 - Crossing 17, 18, 19
 - Microbiological process 18, 19
 - Selection 17, 18, 19
- Exceptions to patentability** 9
 - Animal varieties 15, 301, 302
 - Animals 303, 304, 306, 311–314
 - Morality and ordre public 303, 304, 311–314
 - Discoveries 3, 5, 7, 8
 - Essentially biological processes for production of animals 306, 309
 - Examples from EPO guidelines 306, 309
 - Essentially biological processes for production of plants 256, 270, 273, 284, 285
 - Microorganisms 220
 - Morality and ordre public 9
 - Cloning human beings 9
 - Commercial exploitation 9
 - Diagnostic purpose 12
 - Embryonic stem cells 12
 - Genetic identity 9
 - Human embryos 9, 12, 13, 14
 - Human genes 11
 - Medical benefits 10
 - Publication of invention 9
 - Stem cells 14
 - Therapeutic purpose 12
 - Transgenic animals 10
 - Transgenic plants 10
 - Plant varieties 14, 253, 254
- Experimental data** 29, 30, 58, 59, 60
 - Comparison with prior art 59
 - Experimental set up 60
 - Post published data 31, 32

- Quality 58, 59, 60
- Sufficiency of disclosure 29, 30
- Technical problem 60
 - Support in description 60
- Experimental use** 371
- Farmer's privilege** 373
- Functional features**
 - Clarity 106, 107
 - Sufficiency of disclosure 98
- Gene sequences (scope of protection)** 374
- Germline gene therapy**
 - Novelty 331, 332
- Grant requirements** 27
- Homology**
 - Clarity 109
- Human body** 329
 - As source for antibodies 332
 - Cosmetic methods 332
 - Introduction 329
 - Parts thereof 333
 - Morality and ordre public 333
 - Process claims 335
 - Product claims 333
 - Stem cells 337
 - Use claims 337
 - Process claims 330
 - Product claims 330
 - Product-by-process claims 333, 334
 - Protection under EPC 329
 - Somatic gene therapy 330
 - Summary 342
 - Use claims 332
- Indirect infringement 367
- Industrial application
 - Antibodies 195
 - Criteria for 155
 - No wet chemistry 96
 - Nucleic acids 96
 - Plausibility test 96, 154
 - Proteins 154
- Infringement
 - biological matter 373
 - Bolar provision 368
 - Cease and desist letter 368
 - Claim construction 348
 - Companion diagnostic claims 361
 - Contributory infringement 367
 - Cross-label use 361
 - Direct infringement 367
 - Doctrine of Equivalents 350
 - Experimental use 371
 - Farmer's privilege 373
 - Gene sequences (scope of protection) 374
 - Indirect infringement 367
 - Limitations 368
 - Literal infringement 348
 - Monsanto decision 374
 - Off-label use 361
 - Plant variety rights 366
 - Product/compound claims 355
 - Product-by-process claims 357
 - Purposive construction 353
 - Reach through claims 362
 - Research tools 372
 - Scope of protection 348
 - Screening processes 362
 - Second medical use claims 358
 - SPCs 365
 - Use claims 358
 - Use of the invention 367
- Infringement litigation**
 - Anton Piller Order 378
 - Bifurcation 377
 - Border seizure 343
 - Costs 344
 - Criminal proceedings 375
 - Cross border 345
 - Decision on the merits 377
 - Discovery 378
 - Duration 345
 - Enforcement Directive 378
 - Injunction 346
 - Cross border 346
 - Introduction 343
 - Kort geding 379
 - Preliminary injunction 379
 - Saisie contrefaçon 379
 - Spider in the web 347
 - Torpedo actions 347
 - Venue 343
- Inherent disclosure** 84, 140
 - cDNA versus genomic DNA 102
 - Partial versus whole sequence 102
- Inventive step**
 - Aggregation of features 153
 - Antibodies 189
 - Monoclonal versus polyclonal 189–191, 194
 - Closest prior art 95, 152

- Cross-species hybridization 93, 152
 - Degree of homology 92, 94, 95
 - Desiderata 89, 147
 - Hope to succeed 195
 - Hybridoma, secreted antibody against
 - new vs. known antigen 223
 - Microorganisms 222
 - Microorganism is hybridoma 222
 - Microorganism is not hybridoma 224
 - Transfer of teaching from one micro-organism to another 224–226
 - Monoclonal antibodies
 - Human vs. animal 194
 - Monoclonal versus polyclonal antibodies 223
 - Neighboring field 88
 - Non-predictability of structure 193
 - Nucleic acid
 - Protein known 91
 - Nucleic acids 87
 - Objective technical problem 192
 - Obvious to try 90, 88, 148, 149, 224
 - One-way street situation 150, 224
 - Plausible solution 94, 96
 - No data required 153
 - Pointer in prior art 146
 - Polymers 72
 - Process makes product inventive 150
 - Proteins 145
 - Reasonable expectation of success 90–92, 94, 146, 148–150, 190, 191, 224
 - Certainty not required 154
 - Considered separately from “obvious to try” 225
 - Criteria for 195
 - Recognizable pointer in the prior art 192
 - Selection of closest prior art 151
 - Small molecules 72
 - Surprising effect 72
 - Solution not an improvement 151
 - Technical effect in claims 153, 154
 - Try and see 92, 152, 154, 193
 - Unexplored field 91
 - Unsuitable embodiments 151–153, 159
- Isolated**
- Meaning of 142
- Kort geding** 379
- Legal provisions**
- Directive 2004/27/EC (Bolar Directive) 2, 6, Annex 9
 - Directive 98/44/EC (Biotech Directive) 1–3, 5, 12, 13, 267, 281, 373, Annex 6
 - European Patent Convention (EPC) 2–5, Annexes 1–5
 - Plant varieties
 - International Union for the protection of New Varieties of Plants (UPOV) 6, 14, 66, Annex 8
 - Council Regulation on Community Plant Variety Rights (CPVR) 2, 6, 14, 15, 66–69, Annex 8
 - Supplementary Protection Certificates (SPCs) EC Regulation 1610/96 (Plant Protection Products) 2, 5, Annex 7
 - EC Regulation 469/2009 (Medicinal Products) 2, 5, Annex 7
 - TRIPS Agreement 9
- Life science matter**
- Definition 2
 - History 1
- Literal infringement** 348
- Lundbeck decision** 384
- Mathematical methods**
- Patentable if at least one step is technical 8, 9
- Medical use claims**
- Companion diagnostics / Personalized medicine 25
 - Inherent disclosure in prior art 25, 26
 - Medical devices 26
 - Mixed medical and non-medical effect in claim 24
 - Nature of substance or composition used 24
 - Relationship between Swiss-type and purpose-limited product formats 23, 24, 28
 - Types of features available for delimiting claim
 - Different dosage 22
 - Different patient group 22
 - New technical effect 22
 - Novel disease 22
 - Route/mode of administration 22
 - Treatment regimen 23
- Medicinal products** 51
- Diagnostics 51, 52
 - Surgery 51, 52
 - Treatment of the human body 51, 52

- Methods of treatment** 20, 82, 139
Administration of two or more substances 21
Contraceptive method 139
Conversion to allowable medical uses 21, 22
Cosmetic effect 21
Patentability exclusion applies if at least one step therapeutic 21
Prophylaxis 20, 139
- Microbiological**
Interpretation in case law 19
- Microbiological processes**
Definition 19
- Microorganisms** 38
Clarity and support 235
Deposit 38
Accession number 38
Budapest treaty 39
Recognized depositary institution 38, 39
Discoveries 220
Essentially biological processes 220
Exclusion from patentability 220
General comments and definitions 219
Inventive step 222
Hybridoma, secreted antibody against new vs. known antigen 223
Transfer of teaching from one microorganism to another 224–226
Methods of treatment 221
Morality and ordre public 221
Novelty 221
Isolation of microorganisms from nature 222
Plant cells 290
Process claims 245, 248
Product claims 239, 240, 242, 243, 244
product-by-process claims 243
Same standard for sufficiency of disclosure as other subject matter 230
Use claims 251
- Morality and ordre public** 81, 139
Actions deemed reprehensible by society 10, 11
Animal suffering 11, 12, 303, 312–314
Animals 303, 304, 311–314
Antibodies 186
Breach of public peace / protection of the environment 10, 12
Human body, parts thereof 333
Human genes per se unobjectionable 12
Interpretation in case law 10–14
Legal basis 3, 9, 10
Mere possibility of abuse cannot warrant refusal 11
Microorganisms 221
Nucleic acids 81
Plants 253, 266, 278–281, 284
Proteins 139
Public security and physical integrity of individuals 10
Stem cells 338
Stem cells / embryos 12, 13, 337–340
Values inherent in European culture 10
- Natural plants**
Plant varieties
scope of protection 366
- Naturally occurring products**
Discoveries 7, 8, 80, 83, 138
DNA sequence obtained from gene library 27
First provision and description of isolated product 27
Novelty 27
DNA sequence 27
- Non-patentable matter** 7
Discoveries 7
Products occurring in nature 7, 8
Mathematical methods 7
Data processing 7, 8
Patentable if at least one step is technical 8, 9
- Novelty**
Antibodies 186
By functional limitation 144, 145
Clear and unambiguous teaching 84
Degree of purity 222
Germline gene therapy 331, 332
Inherent disclosure 84
Lack of Probability not enough 144
Microorganisms 221
Enabling disclosure in prior art 221
Isolation of microorganisms from nature 222
Naturally occurring products 27
New composition/sequence 84, 85, 141–143
New parameter 86
Molecular weight 86
Purity 86
Nucleic acids 82
Polymers 71, 72

- Differentiating characteristic 71, 72
- Prior art
 - Content of disclosure as of publication date 188
- Probability vs. certainty of prior art disclosure 222
- Proteins 139
- Purity 86, 140, 144
- Purpose recited in claim 144
- Selection invention 54, 55, 56
- Small molecules 71, 72
 - Differentiating characteristic 71, 72
- Vague feature 187
- Nucleic acids** 79
 - Clarity 106
 - Discoveries 80
 - Gene bank 83
 - In vitro method 82
 - Industrial application 96
 - Inventive step 87
 - Methods of treatment 82
 - Morality and ordre public 81
 - Novelty 82
 - Process claims 131
 - Product claims 109
 - By isolation 134
 - By nucleic acid sequence 119
 - Deposit 124
 - Encoding amino acid sequence 117
 - Functional features 111
 - Genetic engineering or synthesis 132
 - Nucleic acids as essential element 127
 - Parameters 122
 - Types of nucleic acid 129
 - Product-by-process claims 125
 - Sufficiency of disclosure 97
 - Use claims 135
- Nucleotide sequences** 37
 - Sequence listing 37
- Off-label use** 361
- Parameters** 35
 - Antibodies
 - Product claims 209
 - Clarity 48
 - Unusual parameter 48
 - Description 54
 - Measurement method 54
 - Microorganisms
 - Product claims 242
 - Novelty
 - New parameter, e.g. molecular weight, purity 86
- Nucleic acids 122
- Proteins 168
- Sufficiency of disclosure 35
 - Measurement method 36
 - Unusual parameters 36
- Patentability**
 - Basic requirements 7
- Pay-for-delay agreements** 384
- Person skilled in the art** 43
 - Biotechnology 43
 - Team 43, 44
 - Inventive step 44, 45
 - Neighboring field 44
 - Sufficiency of disclosure 44
 - Time of the invention 43
- Plant cells**
 - Microbiological products 296
 - Microorganism 296
 - Not “plant” or “plant variety” 296
- Plant varieties** 14
 - Breeder rights 14
 - Claims embracing plant varieties allowable 15, 254, 255
 - Community Council Regulation on 1
 - Community Plant Protection Right
 - See “CPVR” 66
 - Definition in EPC: homogeneous and stable 14
 - Exclusion from patentability: Legal basis 14, 253, 254
 - Genus of plants 15
 - Interpretation in case law 15–20, 254–256
 - Process for production 15
 - Relationship to CPVR
 - See “CPVR” 3, 6, 14, 15, 66–69
 - Uniform genomic makeup 255
 - Applied to plant parts, incl. Propagating material 288, 290, 292
 - Non-applicability of Art. 64(2) EPC 256, 292, 293
 - Plant cells 290
 - Plants**
 - Clarity 264
 - Discoveries 266, 269, 300
 - Essentially biological processes 253, 255, 269, 273, 276, 284, 300
 - Crossing and selection 257
 - Definition 256, 257
 - Examples 258, 270

- Morality and ordre public 253, 266, 278–281, 284
- Parts of plants 288, 290, 295
- Plant cells: Microorganism, not plant variety 290
- Plant varieties 366
 - Definition 14, 254
 - In claims 254, 255
 - Relation to process claims and Article 64(2) EPC 256, 292, 293
 - Relation to UPOV and CPVR 254
 - Uniform genomic makeup 255
- Process claims 270, 276, 285, 293, 298
- Product claims 275, 269, 282, 290, 296
- Product-by-process claims 20, 259, 269, 275, 276, 290, 291, 296, 297
- Propagating material 266
 - Deposit of 266
- Sufficiency of disclosure 260
 - No different than for non-plant inventions 262
- Use claims 274, 278, 288, 295, 299
- Plausibility test**
- Industrial application 96, 154
- Polymers** 71
 - Inventive step 72
 - Novelty 71, 72
 - Differentiating characteristic 71, 72
- Preliminary injunction** 379
- Prior art**
 - Content of disclosure as of publication date 188
 - Degree of certainty 144
 - Non-enabling/enabling 82–84, 140, 141, 144, 151
- Priority** 40
 - Effective date 40
 - Entitlement to priority 40
 - Multiple priorities 40
 - Same invention 40, 41, 42, 43
 - Disclaimer 41
 - Sequence of proteins 40
- Problem invention** 28
- Process claims**
 - Animals 307, 319, 325
 - Antibodies 216
 - Directly obtained products 367
 - Human body 330
 - Parts thereof 335
 - Low molecular products and polymers 77
 - Microorganisms 245, 248
 - Nucleic acids 132, 134
 - Plants 270, 276, 285, 293, 298
 - Proteins 179, 180
- Processes of analogy** 28, 29
- Product claims**
 - Animals 305, 314, 317, 323
 - Antibodies 203
 - Anticipation by prior art process 144
 - Human body 330
 - Parts thereof 333
 - Low molecular products and polymers 73
 - Microorganisms 239, 240, 242, 243, 244
 - Plants 275, 269, 282, 290, 296
 - Proteins 166
- Product-by-process claims**
 - Animals 20, 304, 305, 317, 323
 - Antibodies 201, 202, 205, 213, 214
 - Criteria for admissibility 201
 - General 46
 - Human body 333, 334
 - Low molecular products and polymers 73
 - Microorganisms 243
 - No limitation of product by process features 243
 - Novelty 141–143, 145, 150
 - Plants 20, 259, 269, 275, 276, 290, 291, 296, 297
 - Process confers new structure 144
 - Proteins 143, 144, 145, 150, 175
 - Scope of protection 357, 358
- Propagating material**
 - Relationship to “biological material” 266
- Proteins** 137
 - Clarity 161
 - Discoveries 138
 - Industrial application 154
 - Inventive step 145
 - Method of treatment 139
 - Morality and ordre public 139
 - Novelty 139
 - Process claims 179
 - by recombinant host cells 180
 - Isolation from nature 179
 - Product claims 166
 - By nucleic acid 171
 - By structure 172
 - Functional features 166
 - Parameters 168
 - Proteins as essential elements 177

- Product-by-process claims 143, 144, 145, 150, 175
- Sufficiency of disclosure 156
- Use claims 183
- Purity**
 - Novelty 86, 140, 144
- Purpose-limited product claims** 21, 28
 - Dosage 22
 - Dosage regimen 23
 - Medical effect 24
 - New indication 22
 - New technical effect 22
 - Non medical effect 24
 - Patient group 22
 - Relevant date 72
 - Route of administration 22
 - Subgroup of patients 23
 - Treatment regimen 23
- Purposive construction** 353
- Reach-through claims (infringement)** 362
- Requirements for grant** 27
- Research tools (infringement)** 372
- Saisie contrefaçon** 379
- Scope of protection (infringement)** 348
- Screening processes (infringement)** 362
- Second medical use claims (infringement)** 358
- Sector Inquiry (pharmaceuticals)** 383
- Selection inventions** 54
 - Broad structural formula 55, 56
 - Compound 55
 - Individualization 55
 - Novelty 54, 55, 56
 - Parameter range 55, 56
- Sequence listing**
 - Amino acid sequences 37
 - Nucleotide sequences 37
 - Prior art sequence 111
- Settlements** 383
- Small molecule** 71
- Small molecules**
 - Inventive step 72
 - Surprising effect 72
 - Novelty 71, 72
 - Differentiating characteristic 71, 72
- Somatic gene therapy**
 - Method of treatment 330
- SPCs** 61
 - Active ingredient 62
 - Basic patent 62
 - Combination of active ingredients 62, 63
 - Different active ingredients 63
 - Duration 65
 - Negative duration 65
 - First market authorization 61
 - Switzerland 62
 - Veterinary market authorization 64
 - Human medicine 61
 - More than one SPC 63, 64
 - Only one SPC 63, 64
 - Plant protection products 61
 - Herbicides 61
 - Insecticides 61
 - Product 62
 - Market authorization 62
 - Scope of protection 65, 66, 365
 - Second medical use claim 64
 - Single active ingredient 62, 63
 - Veterinary medicine 61
- Spider in the web** 347
- Stem cells** 337
 - Adult 340
 - Allowed claims 340, 341
 - Morality and ordre public 338
 - Parthenogenesis 340
 - Pluripotent 339
 - Somatic cellular nuclear transfer 339
 - Totipotent 339
- Sufficiency of disclosure** 29
 - Animals 302, 304
 - Antibodies 195
 - At least one way of performing invention 30
 - Availability of materials needed to perform invention 262, 263
 - Broad claim 30
 - Burden of proof 102, 104, 235
 - Certainty of results 196
 - Chance/fortuitous event 267, 268
 - Chemical inventions and examples 30
 - Claim scope commensurate with technical contribution 232
 - Criteria for 156
 - Denied if independent research project required 231
 - Deposit (for further details see "Deposit") 97, 102, 103, 157, 226
 - Deposit not enough 197
 - Desiderata 199

- Disclosure of patent commensurate with scope of claims 261
- Error in the description unarmful if skilled person could rectify 230–231
- Experimental data 29, 30
 - Post published data 31, 32
- Functional features 33, 34, 35, 98, 105, 158
- Future embodiments 97, 98
- Incorrect data 35
- Inoperable embodiments 97, 98, 159
- Medical effect
 - Criteria for 161
 - Experimental data 160
 - Post-published data 159
- Medical use claims 30, 31
 - Clinical data 31
 - Therapeutic effect 30, 31
- Microorganisms
 - Deposit (for further details see “Deposit”) 226
- Mode of action 198
- No best mode 103
- No example 161
- No insufficiency simply because claim broad 230
- No obligation for deposit 197
- No requirement for examples or data 29, 30, 261
- Nucleic acids 97
- Occasional failure acceptable 197, 200
- One way is enough 98, 99
- Parameters 35, 160
 - Different test results 158, 159
 - Measurement method 36
 - Reliable test 160, 161
 - Unusual parameters 36
- Plants 260
 - Chance/fortuitous event 267, 268
- Post-published data 31, 231
- Process claims
 - Means to obtain product 199
- Proteins 156
- Public availability of microorganism 83
- Putting into practice 99, 106
- Reach-through claim 33, 34, 35
- Reduction to practice 83
- Relationship between breadth of claim and level of disclosure 29, 30
- Reproducibility 83
 - Of example 99, 100, 101, 156, 196
 - With certainty 233–235
- Requirement for example 29, 30, 105, 160, 198
- Same standard for invention and prior art 104
- Serious doubts 160
- Trial and error 104, 199
- Undue burden 102, 104
 - Individual steps vs. total amount of effort needed to perform invention 264
 - Time-consuming work 197, 198
 - Whole range claimed 104
- Supplementary protection certificate**
 - History 1, 2; see “SPCs”
- Supplementary protection certificates** see “SPCs”
- Support by description** 49
 - Entire scope 50
 - Formal support 50
 - Technical support 50
- Technology Transfer Regulation** 382
- Torpedo actions** 347
- Treatment of human or animal body** 20
 - Companion diagnostics 25, 26
 - Cosmetic effect 21
 - Curative treatment 20
 - Diagnostic method 24, 25
 - Medical device 26
 - Medical treatment 20
 - Non therapeutic treatment 21
 - Personalized medicine 25
 - Prophylactic treatment 20
 - Purpose-limited product claims 21
 - Dosage 22
 - Dosage regimen 23
 - Medical effect 24
 - New indication 22
 - New technical effect 22
 - Non medical effect 24
 - Patient group 22
 - Route of administration 22
 - Subgroup of patients 23
 - Treatment regimen 23
 - Therapeutic treatment 21
 - Treatment by surgery 26
- Undue burden**
 - Sufficiency of disclosure 102, 104, 197, 198, 264
 - Time-consuming work 197, 198

Unified Patent Court

- Central division 386
- Court of Appeals 387
- Introduction 386
- Jurisdiction 387
- Local divisions 386
- Panels 389
- Parties 390
- Preliminary injunctions 390
- Procedural issues 391
- Provisional measures 390
- Regional divisions 386
- Representatives before 390
- Structure 386
- Transitional period 388
- UPC Agreement 386

Unitary Patent

- Introduction 385
- Language 385
- Opt out 388

Unity

- A posteriori 53
- A priori 53
- Divisional applications 53

- First and second medical uses 54
- Interrelated products 53
 - Final product 53
 - Intermediates 53
- Partial search report 52
- Single general inventive concept 52
- Special technical feature 52

Use claims

- Animals 309, 321, 327
- Antibodies 218
- Human body 332
 - Parts thereof 337
- Low molecular products and polymers 78
- Microorganism 251
- Nucleic acids 135
- Plants 274, 278, 288, 295, 299
- Proteins 183

Use claims/purpose-limited product claims (general aspects)

- infringement 358

Use of the invention

- 367
- Zebrafish** 311, 326